CompletedPhase 2NCT02071940
PLX3397 KIT in Acral aNd mucOsal Melanoma
Studying Malignant melanoma of the mucosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Christie NHS Foundation Trust
- Principal Investigator
- Paul Lorigan, MBBCH, FRCPThe Christie NHS Foundation Trust
- Intervention
- PLX3397(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2021
Study locations (8)
- The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
- Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, Wales, United Kingdom
- St James' University Hospital, Leeds, Yorkshire, United Kingdom
- Cancer Clinical Trials Centre- Weston Park Hospital, Sheffield, Yorkshire, United Kingdom
- Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Cambridge, United Kingdom
- The Royal Marsden NHS Foundation Trust, London, United Kingdom
- Oxford University Hospitals NHS Trust- Churchill Hospital, Oxford, United Kingdom
Collaborators
Cancer Research UK · Christie Charitable Funds
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02071940 on ClinicalTrials.govOther trials for Malignant melanoma of the mucosa
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06797297A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyInnovent Biologics (Suzhou) Co. Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05661955A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.BeiGene
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05089370Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaUniversity of Colorado, Denver
- RECRUITINGPHASE2NCT04879654Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic SurgeryEye & ENT Hospital of Fudan University